日本高潮视频在线观看-亚洲中文字幕永不卡-精品亚洲一区二区三区-伦理片夜夜躁狠狠躁日日躁-日本最新免费不卡二区-国产精品口爆一区二区三区-av一区二区三区高清-大鸡巴疯狂抽插小穴视频-日韩中文国产在线观看免费视频

Your Good Partner in Biology Research

  1. Home
  2. 抗體
  3. 科研級生物類似抗體
  4. SSTR2 (Tidutamab Biosimilar) Recombinant Monoclonal Antibody

SSTR2 (Tidutamab Biosimilar) Recombinant Monoclonal Antibody

  • 貨號：
    CSB-RA022725MB1HU
  • 規(guī)格：
    ￥83486
  • 其他：

產(chǎn)品詳情

  • 產(chǎn)品描述：
    SSTR2 (Tidutamab Biosimilar Antibody) 重組單克隆抗體是一種針對生長抑素受體2（Somatostatin receptor type 2，簡稱SSTR2），其別名包括SS-2-R、SS2-R、SS2R及SRIF-1。該抗體以重組人SSTR2蛋白制備，具有高度的種屬反應性，主要針對人類SSTR2靶點發(fā)揮作用。SSTR2是一種G蛋白偶聯(lián)受體，在多種神經(jīng)內(nèi)分泌腫瘤及部分實體瘤中高表達，通過與生長抑素類似物結(jié)合調(diào)控細胞增殖與激素分泌，成為腫瘤診斷與治療的重要分子靶點。 Tidutamab Biosimilar藥物展現(xiàn)出顯著的應用潛力。目前，針對神經(jīng)內(nèi)分泌腫瘤（如胃腸胰神經(jīng)內(nèi)分泌腫瘤、肺神經(jīng)內(nèi)分泌腫瘤）的臨床試驗正在推進，其作用機制包括通過抗體依賴性細胞毒性（ADCC）和補體依賴性細胞毒性（CDC）特異性殺傷高表達SSTR2的腫瘤細胞，同時可能通過阻斷受體信號通路抑制腫瘤生長。此外，該抗體研發(fā)的藥物與放射性核素偶聯(lián)后可用于腫瘤的診斷成像（如PET顯像）及放射性靶向治療，為個體化治療提供精準指導。早期臨床數(shù)據(jù)顯示，其在晚期神經(jīng)內(nèi)分泌腫瘤患者中具有良好的安全性和初步療效，尤其對傳統(tǒng)治療耐藥的患者可能帶來新的治療選擇。 SSTR2重組單克隆抗體是探究SSTR2生物學功能的關(guān)鍵工具。在基礎(chǔ)研究中，可用于檢測SSTR2在不同組織和細胞系中的表達水平，通過方法分析其與腫瘤發(fā)生、發(fā)展的關(guān)聯(lián)；在功能實驗中，可通過中和或激活SSTR2信號通路，研究其對細胞凋亡、血管生成及腫瘤微環(huán)境的影響。此外，該抗體還可用于構(gòu)建腫瘤動物模型，評估靶向SSTR2類似物遞送系統(tǒng)（如抗體-藥物偶聯(lián)物）的有效性，為新型抗腫瘤藥物的研發(fā)提供實驗基礎(chǔ)。由于其種屬反應性限定為人類，研究中需注意選擇人源細胞或組織樣本，以確保實驗結(jié)果的臨床轉(zhuǎn)化價值。 綜上，SSTR2 (Tidutamab Biosimilar Antibody) 重組單克隆抗體不僅為神經(jīng)內(nèi)分泌腫瘤等疾病的臨床治療開辟了新路徑，也為深入解析SSTR2的生理病理機制提供了可靠的科研工具，具有重要的臨床轉(zhuǎn)化意義和科學研究價值。
  • Uniprot No.：
  • 基因名：
  • 別名：
    SSTR2; Somatostatin receptor type 2; SS-2-R; SS2-R; SS2R; SRIF-1
  • 反應種屬：
    Human
  • 免疫原：
    Recombinant Human SSTR2 protein
  • 免疫原種屬：
    Homo sapiens (Human)
  • 標記方式：
    Non-conjugated
  • 克隆類型：
    Monoclonal
  • 濃度：
    It differs from different batches. Please contact us to confirm it.
  • 保存緩沖液：
    0.01M PBS，pH7.4
  • 產(chǎn)品提供形式：
    Liquid
  • 應用說明：
    Validation Status Application-specific performance (e.g., in flow cytometry, ELISA, IHC or other assay formats) has not yet been experimentally verified by CUSABIO. Users are advised to determine the optimal working conditions empirically in their own assay systems. Guaranteed Quality ① Antibody purity?> 95% tested by SDS-PAGE. ② Endotoxin level < 0.1EU/ug tested by LAL method.
  • 儲存條件：
    Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
  • 貨期：
    In stock
  • 用途：
    It is a non-therapeutic biosimilar antibody, owning the same variable region from the corresponding approved therapeutic antibody. In conclusion, it is a research-grade biosimilar antibody and expressed in mammalian cell, which can be directly used as positive controls in drug discovery or used for rapid verification of the biological functions of target protein.

產(chǎn)品評價

靶點詳情

  • 功能：
    Receptor for somatostatin-14 and -28. This receptor is coupled via pertussis toxin sensitive G proteins to inhibition of adenylyl cyclase. In addition it stimulates phosphotyrosine phosphatase and PLC via pertussis toxin insensitive as well as sensitive G proteins. Inhibits calcium entry by suppressing voltage-dependent calcium channels. Acts as the functionally dominant somatostatin receptor in pancreatic alpha- and beta-cells where it mediates the inhibitory effect of somatostatin-14 on hormone secretion. Inhibits cell growth through enhancement of MAPK1 and MAPK2 phosphorylation and subsequent up-regulation of CDKN1B. Stimulates neuronal migration and axon outgrowth and may participate in neuron development and maturation during brain development. Mediates negative regulation of insulin receptor signaling through PTPN6. Inactivates SSTR3 receptor function following heterodimerization.
  • 基因功能參考文獻：
    1. SSTR2A expression is infrequent in astrocytomas and negative in the majority of glioblastomas where it is of no prognostic significance. In contrast, oligodendrogliomas show intense membranous and cytoplasmic SSTR2A expression. PMID: 28467778
    2. The results of this study showed the SSTR2 expression was lower in patients pretreated with LA-SSA/PEGV compared to the drug-naive acromegalic patients. PMID: 27455094
    3. IHC of SSTR subtypes in the different cohorts showed SSTR2 staining intensity scores higher than SSTR5 in TSHoma, acromegaly and prolactinoma, whereas the expression of SSTR5 was stronger than SSTR2 in corticotropinoma and NFPA. PMID: 28434012
    4. SSTR2 was significantly hypermethylated in colorectal cancer tissues when compared with adjacent normal colorectal tissues. PMID: 28782576
    5. This study investigated the presence of progenitor/stem cells in non-functioning pituitary tumors (NFPTs) and tested the efficacy of dopamine receptor type 2 (DRD2) and somatostatin receptor type 2 (SSTR2) agonists to inhibit in vitro proliferation PMID: 28120505
    6. expression of MDM2, somatostatin receptor 2A, and PD-L1 in follicular dendritic cell sarcoma PMID: 27402219
    7. Combination treatment increased both SSTR2 and SSTR5 mRNA and protein levels in DU-145 cells. The data suggest that this combination therapy may be a good candidate for patients with advanced metastatic Prostate cancer (PCa) do not respond to androgen deprivation. PMID: 26531719
    8. although the limited number of cases with adequate term follow-up, SSTR-2A expression could be a prognostic factor and somatostatin analogs therapeutic candidate for SmCCs of the bladder as these tumors show high percentage of SSTR-2A expression PMID: 25906124
    9. SSTR2 expression was tested in GH-secreting adenomas from 60 patients with acromegaly who had undergone pituitary surgery, 36 of whom had received octreotide with varying levels of response. Its expression was not correlated with baseline or post-octreotide GH or IGF-1 levels or tumor volume. PMID: 25008035
    10. Filamin-A is required to mediate SSTR2 effects in pancreatic neuroendocrine tumours PMID: 26733502
    11. SSTR2 promoter hypermethylation might be associated with the risk and progression of laryngeal squamous cell carcinoma in males. PMID: 26796520
    12. VPA was observed to stimulate the expression of somatostatin receptor type 2 (SSTR2). PMID: 26211366
    13. Results show that histological subtyping of pituitary tumor correlated with SSTR2, E cadherin and p27kip protein levels and these may serve as useful biomarkers for prognosis. PMID: 26391562
    14. there is an elevation in CXCR4 and a decrease in SSTR2A expression with increasing malignancy in gastroenteropancreatic neuroendocrine neoplasms PMID: 26259237
    15. mir-185 regulates the expression of SSTR2 in GH-secreting pituitary adenoma. The staining intensity of SSTR2 is stronger in adenoma samples than controls. PMID: 26036598
    16. Data indicate that somatostatin receptor scintigraphy (SRS) and immunohistochemical results for somatostatin and dopamine receptors sstr2, sstr3, sstr5 and D2R were compared in neuroendocrine neoplasms tissues. PMID: 25808161
    17. CD56 marker is a useful alternative that is comparable to SSTR2A for the diagnosis of phosphaturic mesenchymal tumors. PMID: 26339384
    18. The number of SSTR-2-expressing cells was significantly smaller in the patients with Crohn's disease than that in those with the unchanged mucosa and in those with indeterminate (unclassified) colitis. PMID: 26978232
    19. In pancreatic neuroendocrine tumors, the primary tumor and metastases differ significantly in their SSTR2A expression. PMID: 25872131
    20. Study demonstrates the first evidence of SST2R expression and somatostatin receptor scintigraphy positivity in pancreatic serous cystadenomas. PMID: 25872132
    21. Somatostatin receptors were expressed in a high proportion of merkel cell carcinomas, although expression was heterogeneous between tumours and was not associated with disease severity. PMID: 25765179
    22. SSTR2 gene expression was dysregulated in the anterior cingulate of bipolar patients. PMID: 26238605
    23. Low SSTR2 expression is associated with pancreatic cancer. PMID: 25890201
    24. e hSSTr2 gene can act as not only a reporter gene for in vivo imaging, but also a therapeutic gene for local radionuclide therapy. PMID: 25879040
    25. Somatostatin type 2 receptor, a clinically crucial molecular target, shows variable and unpredictable expression in neuroendocrine neoplasms irrespective of tumor grade. PMID: 25591947
    26. This study indicated that SSTR2 may be associated with the selective vulnerability of the noradrenergic system in Alzheimer's disease. PMID: 25676386
    27. sST2 is proposed as a biomarker for progressive vascular fibrosis, and the involvement of sST2 in the pathogenesis of limited cutaneous systemic sclerosis may be exploited therapeutically. PMID: 26095613
    28. The expression of VEGF and SSTR2 were associated with progression and prognosis of gastric cancer. PMID: 26158180
    29. SSTR2 and SSTR5 protein levels were induced as compared to any agent alone. PMID: 25925002
    30. SSTR 5 was shown to be the main receptor subtype in the analysed differentiated or anaplastic thyroid malignancies, whereas SSTR 2 was found only in a small percentage. PMID: 24967740
    31. SSTR2A and SSTR3 are more likely to be expressed in SDH-deficient pheochromocytomas/paragangliomas compared with tumors demonstrating normal SDHB staining pattern. PMID: 25554089
    32. Relationships between SSTR2A and breast or prostate cancer showed low concordance between CpGs methylation grade and cancer. PMID: 25635370
    33. SSTR2 expression seems an important factor in the pathogenesis of prostate cancer PMID: 25010045
    34. agonist-selective sst2 receptor internalization is regulated by multi-site phosphorylation of its carboxyl-terminal tail. PMID: 24565897
    35. Filamin A is involved in SST2 stabilization and signaling in tumoral somatotrophs, playing both a structural and functional role. PMID: 24828612
    36. SSTR2 is overexpressed in gastric and duodenal neuroendocrine tumors PMID: 24565507
    37. We genotyped two single nucleotide polymorphisms (SNPs) in genes of importance for respiratory control: P2RY1 (adenosine diphosphate/adenosine triphosphate receptor) and SSTR2 (somatostatin receptor). PMID: 23828624
    38. ZAC1 and SSTR2 are down-regulated in non-functioning pituitary adenomas but not in somatotropinomas. PMID: 24098585
    39. Whereas sst2 receptors might play a primary role in the differentiation and regulation of TSH, LH, and FSH cells, sst5 receptors appear to be mainly involved in GH regulation from birth onward PMID: 24189142
    40. The analyses of this study demonstrated specific upregulation of sst 2 mRNA in medulloblastoma PMID: 23677175
    41. We studied the expression of SSTR(2A) and SSTR(5) with new procedures in 108 pituitary tumors PMID: 24182563
    42. Somatostatin receptor-2 positivity, either focal or diffuse, does not seem to predict prognosis in gastroenteropancreatic neuroendocrine tumors. PMID: 23794313
    43. Because of its diffuse strong expression and widespread availability, immunohistochemistry for SSTR2A is useful to confirm the diagnosis of phosphaturic mesenchymal tumors in an appropriate setting particularly if material is limited. PMID: 24060005
    44. mRNA levels of SSTR2a, SSTR3 and SSTR5 in neuroendocrine lung cancer affected patients, were determined. PMID: 21503779
    45. Low somatostatin receptor subtype 2, but not dopamine receptor subtype 2 expression is associated with the lack of biochemical response of somatotropinomas to treatment with somatostatin analogs PMID: 22472799
    46. Results suggest that targeting adenoviral vectors to sstr2A could provide a new strategy for the efficient transfer of genes to glioblastoma cells. PMID: 22592599
    47. Report down-regulation of SSTR-2 expression in operable hepatocellular carcinomas. PMID: 22640914
    48. Data suggest that somatostatin-14 inhibits secretion from alpha and beta pancreatic cells by activating GIRK (G protein-coupled inwardly-rectifying potassium channel) and inhibiting exocytosis; these effects are mediated by SSTR2 in both cell types. PMID: 22932785
    49. Mean cortical SSTR2 mRNA levels were significantly (19%) lower in the subjects with schizophrenia compared to controls. PMID: 21215273
    50. Data show that the aspartic acid changes at position 89 to either Ala, Leu, or Arg generated mutant somatostatin receptor subtype 2 (SSTR2) with varying expression profiles and a complete inability to bind somatostatin-14 (SST). PMID: 22495673

    顯示更多

    收起更多

  • 亞細胞定位：
    Cell membrane; Multi-pass membrane protein. Cytoplasm. Note=Located mainly at the cell surface under basal conditions. Agonist stimulation results in internalization to the cytoplasm.
  • 蛋白家族：
    G-protein coupled receptor 1 family
  • 組織特異性：
    Expressed in both pancreatic alpha- and beta-cells (at protein level). Expressed at higher levels in the pancreas than other somatostatin receptors. Also expressed in the cerebrum and kidney and, in lesser amounts, in the jejunum, colon and liver. In the
  • 數(shù)據(jù)庫鏈接：

    HGNC: 11331

    OMIM: 182452

    KEGG: hsa:6752

    STRING: 9606.ENSP00000350198

    UniGene: Hs.514451



×
生命科學計算平臺